New stock news | Haina Pharmaceuticals submits application to Hong Kong Stock Exchange

According to the Zhitong Finance and Economics APP, as disclosed by the Hong Kong Stock Exchange on November 7th, Nanjing Haven Pharmaceutical Technology Co., Ltd. (Haven Pharmaceutical) has submitted an application to list on the main board of the Hong Kong Stock Exchange, with China International Capital Corporation Limited as its exclusive sponsor. According to the prospectus, Haven Pharmaceutical is an integrated pharmaceutical research and manufacturing company that provides CXO services; at the same time, the company has a proprietary product pipeline, mainly commercialized through pharmaceutical technology transfer. According to a Frost & Sullivan report, during the previous accounting period and until the latest practical date, Haven Pharmaceutical ranked second in the total number of approved clinical trials and marketing approvals among CXO service providers engaged in drug technology transfer in China. According to the same source, the company also ranked second in the total number of clinical trial and marketing approval applications submitted during the same period.